Wells Fargo
CRDL

Wells Fargo’s Cardiol Therapeutics CRDL Stock Holding History

Wells Fargo’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$24 – 7175
2025
Q1 		$24 Sell
25
-1,975
-99% -$2.42K ﹤0.01% 6608
2024
Q4 		$2.57K Hold
2,000
– – ﹤0.01% 6157
2024
Q3 		$3.98K Sell
2,000
-1,000
-33% -$2.08K ﹤0.01% 5958
2024
Q2 		$5.98K Hold
3,000
– – ﹤0.01% 5844
2024
Q1 		$5.38K Buy
+3,000
New +$4.04K ﹤0.01% 5880
2023
Q4 		– Sell
-150
Closed -$137 – 7607
2023
Q3 		$137 Buy
+150
New +$143 ﹤0.01% 6683

Other funds holding CRDL

TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return

Wells Fargo's CRDL Position: Q2 2025 in Review

Wells Fargo sold out of Cardiol Therapeutics (CRDL) in Q2 2025, closing a stake of 25 shares — an estimated $24 sold.

Wells Fargo first reported a position in CRDL in Q3 2023 and held it in 6 quarters. The position peaked at $5.98K in Q2 2024. 38 funds tracked by Wall St. Rank hold CRDL as of Q2 2025.

  • Wells Fargo reported no remaining Cardiol Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wells Fargo sold 25 Cardiol Therapeutics shares in Q2 2025, an estimated $24.
  • Wells Fargo first reported a position in Cardiol Therapeutics in Q3 2023 and held it in 6 quarters.
  • Wells Fargo's Cardiol Therapeutics position peaked at $5.98K in Q2 2024.
  • 38 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2025.

Based on Wells Fargo's 13F filing for Q2 2025, filed 14 Aug 2025.